Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Pabinger

Showing results (281-290 of 367) with videos related to

Pageof 37
Sort By:
Thrombosis Research|August 28, 2017
Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI)Oliver Königsbrügge, Matthias Lorenz, Martin Auinger, et al.
Annals of Hematology|December 27, 2016
Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown causeJohanna Gebhart, Sylvia Kepa, Stefanie Hofer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 18, 2019
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim resultsShadan Lalezari, Mark T Reding, Ingrid Pabinger, et al.
Research and Practice in Thrombosis and Haemostasis|February 26, 2025
Altered clot structure in pregnant women who will develop postpartum hemorrhageClaire de Moreuil, Brigitte Pan-Petesch, François Anouilh, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|September 17, 2019
Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and deathFlorian Posch, Stefanie Hofer, Johannes Thaler, et al.
Research and Practice in Thrombosis and Haemostasis|March 13, 2023
Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint statusJudit Rejtő, Daniel Kraemmer, Ella Grilz, et al.
Blood Advances|September 4, 2024
Plasmin generation analysis in patients with bleeding disorder of unknown causeDino Mehic, Stéphanie E Reitsma, Claire de Moreuil, et al.
Thrombosis Research|October 8, 2021
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopeniaJohannes Thaler, Petra Jilma, Nazanin Samadi, et al.
Therapeutic Advances in Hematology|April 28, 2023
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: <i>post hoc</i> analysis from the PROTECT VIII studyMark T Reding, Ingrid Pabinger, Pål Andrè Holme, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 5, 2021
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension studyMark T Reding, Ingrid Pabinger, Pal Andre Holme, et al.
Pageof 37

Showing results (281-290 of 367) with videos related to

Sort By:
Pageof 37
Thrombosis Research|August 28, 2017
Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VIVALDI)Oliver Königsbrügge, Matthias Lorenz, Martin Auinger, et al.
Annals of Hematology|December 27, 2016
Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown causeJohanna Gebhart, Sylvia Kepa, Stefanie Hofer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 18, 2019
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim resultsShadan Lalezari, Mark T Reding, Ingrid Pabinger, et al.
Research and Practice in Thrombosis and Haemostasis|February 26, 2025
Altered clot structure in pregnant women who will develop postpartum hemorrhageClaire de Moreuil, Brigitte Pan-Petesch, François Anouilh, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|September 17, 2019
Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and deathFlorian Posch, Stefanie Hofer, Johannes Thaler, et al.
Research and Practice in Thrombosis and Haemostasis|March 13, 2023
Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint statusJudit Rejtő, Daniel Kraemmer, Ella Grilz, et al.
Blood Advances|September 4, 2024
Plasmin generation analysis in patients with bleeding disorder of unknown causeDino Mehic, Stéphanie E Reitsma, Claire de Moreuil, et al.
Thrombosis Research|October 8, 2021
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopeniaJohannes Thaler, Petra Jilma, Nazanin Samadi, et al.
Therapeutic Advances in Hematology|April 28, 2023
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: <i>post hoc</i> analysis from the PROTECT VIII studyMark T Reding, Ingrid Pabinger, Pål Andrè Holme, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 5, 2021
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension studyMark T Reding, Ingrid Pabinger, Pal Andre Holme, et al.
Pageof 37